Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ametinib plus intrathecal pemetrexed for EGFR-mutant lung cancer with meningeal metastases after first-line TKI failure
ChiCTR2100047017Phase 2Recruiting
- Sponsor
- The 2nd Affiliated Hospital of Harbin Medical University
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib and pemetrexed in Non-small cell lung cancer adenocarcinoma (NSCLC) and Carcinomatous Meningitis (CM), sponsored by The 2nd Affiliated Hospital of Harbin Medical University. Primary endpoints: Overall survival, Progression-free survival and 1 more. Started Jun 2021; status: recruiting.
02
Drugs
imatinibpemetrexed
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)Carcinomatous Meningitis (CM)
Beyond the preview
Go deeper on ChiCTR2100047017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047017.